EXELIXIS INC (EXEL) Stock Price, Quote, News and Overview
NASDAQ:EXEL - Nasdaq - US30161Q1040 - Common Stock - Currency: USD
EXEL Quote, Performance and Key Statistics
42.86
-0.86 (-1.97%)
The current stock price of EXEL is 42.86 USD. In the past month the price increased by 15.18%. In the past year, price increased by 108.36%.
EXEL Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About EXEL
Company Profile
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. The company is headquartered in Alameda, California and currently employs 1,147 full-time employees. The company went IPO on 2000-04-11. The firm has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. The company is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The firm's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Company Info
EXELIXIS INC
1851 Harbor Bay Parkway
Alameda CALIFORNIA 94502 US
CEO: Michael M. Morrissey
Employees: 1147
Phone: 16508377000
EXELIXIS INC / EXEL FAQ
What is the stock price of EXELIXIS INC today?
The current stock price of EXEL is 42.86 USD. The price decreased by -1.97% in the last trading session.
What is the ticker symbol for EXELIXIS INC stock?
The exchange symbol of EXELIXIS INC is EXEL and it is listed on the Nasdaq exchange.
On which exchange is EXEL stock listed?
EXEL stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for EXELIXIS INC stock?
26 analysts have analysed EXEL and the average price target is 38.71 USD. This implies a price decrease of -9.69% is expected in the next year compared to the current price of 42.86. Check the EXELIXIS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is EXELIXIS INC worth?
EXELIXIS INC (EXEL) has a market capitalization of 11.81B USD. This makes EXEL a Large Cap stock.
How many employees does EXELIXIS INC have?
EXELIXIS INC (EXEL) currently has 1147 employees.
What are the support and resistance levels for EXELIXIS INC (EXEL) stock?
EXELIXIS INC (EXEL) has a support level at 42.85. Check the full technical report for a detailed analysis of EXEL support and resistance levels.
Is EXELIXIS INC (EXEL) expected to grow?
The Revenue of EXELIXIS INC (EXEL) is expected to grow by 8.42% in the next year. Check the estimates tab for more information on the EXEL EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy EXELIXIS INC (EXEL) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of EXEL, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of EXEL, evaluating the profitability, health, valuation and growth aspects
- EXELIXIS INC (EXEL) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- EXELIXIS INC (EXEL) Sales and EPS estimates to see what analysts future expectations are.
- EXELIXIS INC (EXEL) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- EXELIXIS INC (EXEL) Insider and Institutional Ownership to learn about the owners and their transactions.
- EXELIXIS INC (EXEL) Stock Chart to make your own analysis
- EXELIXIS INC (EXEL) Latest news and press-releases to stay up to date.
Does EXELIXIS INC (EXEL) stock pay dividends?
EXEL does not pay a dividend.
When does EXELIXIS INC (EXEL) report earnings?
EXELIXIS INC (EXEL) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of EXELIXIS INC (EXEL)?
The PE ratio for EXELIXIS INC (EXEL) is 19.48. This is based on the reported non-GAAP earnings per share of 2.2 and the current share price of 42.86 USD. Check the full fundamental report for a full analysis of the valuation metrics for EXEL.
What is the Short Interest ratio of EXELIXIS INC (EXEL) stock?
The outstanding short interest for EXELIXIS INC (EXEL) is 7.12% of its float. Check the ownership tab for more information on the EXEL short interest.
EXEL Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to EXEL. When comparing the yearly performance of all stocks, EXEL is one of the better performing stocks in the market, outperforming 96.85% of all stocks.
EXEL Fundamental Analysis
ChartMill assigns a fundamental rating of 8 / 10 to EXEL. Both the health and profitability get an excellent rating, making EXEL a very profitable company, without any liquidiy or solvency issues.
EXEL Financial Highlights
Over the last trailing twelve months EXEL reported a non-GAAP Earnings per Share(EPS) of 2.2. The EPS increased by 205.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 24.04% | ||
| ROA | 17.68% | ||
| ROE | 23.23% | ||
| Debt/Equity | 0 |
EXEL Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to EXEL. The Buy consensus is the average rating of analysts ratings from 26 analysts.
For the next year, analysts expect an EPS growth of 22.46% and a revenue growth 8.42% for EXEL